Gopal Pundlik Jadhav, PhD

Board Membership, Creighton University, Health ans Safety

Assistant Professor

Contact

GopalJadhav@creighton.edu
School of Medicine
Pharmacology and Neuroscience
Translational Hearing
CRISS III - Criss 3 - 558A

Gopal Pundlik Jadhav, PhD

Board Membership, Creighton University, Health ans Safety

Assistant Professor

After earning a Masters of Pharmacy from Pune University (India) in 1998, Dr. Gopal worked as a synthetic chemist for a year and taught medicinal chemistry for three years before beginning a PhD at the University of Nottingham (UK). In the five years after his Ph.D., he worked as a post-doctoral research fellow on three projects: one on cancer research, financed by the BBSRC in the UK; another on drug discovery, funded by the Wellcome Trust; and one on osteoporosis, funded by the MRC in the UK.
After that, Dr. Jadhav worked for about two years as a senior research scientist at GlaxoSmithKline's RD Alternative Discovery & Development (Madrid Trescants, Spain) on a collaborative project that involved structural optimization of the hPDE4 inhibitor GSK675728A to produce novel pharmacophore(s) as potent TbrPDE1 inhibitors that are selective over hPDEs in the management of African sleeping sickness (CNS disorder). 
Dr. Gopal started working as a postdoctoral researcher at Creighton University in June 2016 and was later promoted to assistant professor of medicinal chemistry in early 2017. He is presently tenure track faculty in the school of medicine working under Dr. Peter Abel.

Lab Research Focus: Dr. Jadhav’s Lab is aimed at;
A) Molecular docking and Structure Activity Relationship (SAR) based small molecular drug discovery to tackle biological problems such as Neuroinfllamatory disorders, Cancers, Noise induced hearing loss (NIHL) and Antibiotic resistant Bacterial infections. Current projects involve (1) Development of Triggering receptors expressed on myeloid cells-1 (TREM1) inhibitors to treat neuronal disorders, NIHL and liver cancer. (2) Development of small molecules as Mvfr inhibitors to treat antibiotic resistant Pseudomonas aeruginosa infections. 
B) PROTAC (Proteolysis targeting chimeras) therapeutics: to address liver cancer and Neuroinflmmations.
C) Dual conjugates of Latanoprost acid  to release Nitrous oxide (NO) and Hydrogen suflide (H2S) in the management of gloucoma.

Curriculum Vitae

Teaching Interests

  • Synthetic organic chemistry: Hands on experience in modern synthetic organic chemistry like multi-step syntheses of drug like molecules, heterocycles, peptides, etc., parallel synthesis using Radley’s. Independent planning and execution of SAR.

Research Focus

Drug discovery in Cardiac and cardiovascular disorders
Drug discovery in immuno and inflammatory disorders
Drug discovery in Quorum sensing
Drug discovery in Highly neglected diseases
 

Department

Pharmacology and Neuroscience

Position

Assistant Professor

Books

  • Laser Therapies : Types, Uses and Safety
    Hati Santanu, Laser technology to facilitate drug discovery and development processes [Book Chapter] 2020

Publications

  • Molecules (Basel, Switzerland)
    Kaur Ishwinder, The Discovery of Substituted 5-(2-Hydroxybenzoyl)-2-Pyridone Analogues as Inhibitors of the Human Caf1/CNOT7 Ribonuclease
    29:18, p. 4351 2024
  • BULLETIN OF THE UNIVERSITY OF KARAGANDA-CHEMISTRY
    Bhimanwar R., Prospective Hybrid Molecules with Dual Anti-Viral and Anti-Thrombotic Activity Against the SARS-CoV-2 Infection and Its Associated Complications Employing in Silico Studies, p. 76 - 88 2022
  • Jadhav Gopal P., Surface plasmon resonance, Orbitrap mass spectrometry and Raman advancements 2020
  • FEBS Open Bio
    Airhihen Blessing, 1-Hydroxy-xanthine derivatives inhibit the human Caf1 nuclease and Caf1-containing nuclease complexes via Mg 2+ -dependent binding
    9:4, p. 717 - 727 2019
  • Journal of Cardiovascular Development and Disease
    Kouassi Kouassi T., TREM-1; Is it a pivotal target for cardiovascular diseases?
    5:3 2018
  • Molecules
    Bhosale Jitendra D., FacIle syntheses and molecular-docking of novel substituted 3,4-dimethyl-1H-pyrrole-2-carboxamide/ carbohydrazide Analogues with antimicrobial and antifungal properties
    23:4 2018
  • FASEB Journal
    Baker Jillian G., Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease
    31:7, p. 3150 - 3166 2017
  • Bioorganic and Medicinal Chemistry Letters
    Jadhav Gopal P., Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1
    25:19, p. 4219 - 4224 2015
  • Nucleic Acids Research
    Maryati Maryati, A fluorescence-based assay suitable for quantitative analysis of deadenylase enzyme activity
    42:5, p. e30 2014
  • Journal of Medicinal Chemistry
    Jadhav Gopal P., Immunosuppressive but non-LasR-inducing analogues of the pseudomonas aeruginosa quorum-sensing molecule N-(3-Oxododecanoyl)-l-homoserine Lactone
    54:9, p. 3348 - 3359 2011
  • Indian Drugs
    Jadhav Gopal P., Estimation of proxicam β-cyclodextrine from marketed formulations by RP-HPLC
    36:8, p. 506 - 508 1999
  • Indian Drugs
    Kale A. D., Spectrophotometric estimation of dicyclomine hydrochloride from combined dosage forms by ion pair complex
    35:11, p. 718 - 720 1998
  • Indian Drugs
    Jadhav Gopal P., Simultaneous estimation of nalidixic acid and metronidazole using uv/visible spectrophotometer
    35:8, p. 475 - 480 1998
  • Indian Journal of Pharmaceutical Sciences
    Jadhav G. P., Simultaneous UV-spectrophotometric estimation of nalidixic acid and metronidazole from various multicomponent formulations
    60:4, p. 246 - 248 1998

Presentations

  • Invited talk on " The development of selective Beta 1adrenergic receptor inhibitors for the management of Cardiovascular diseases".Venue: SGMSPM's Dnyanvilas College of Pharmacy, Pune, India.https://www.dvcop.com 2018
  • Invited talk on "TREM-1 drug discovery, a pivotal target for Cardiovascular disorders"Venue: STES's Sinhgad College of Pharmacy, Pune, India.www.sinhgad.edu 2018